NCT00295178

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (planned)
• Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: * Time to erythema margin cessation to progress * Time to defervescence * Time to hospital discharge following relief of the presenting cellulitis or erysipelas * Degree of improvement of the following signs and symptom of cellulitis or erysipelas including * Degree of improvement of cellulitis-related pain and swelling as reported by subjects Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.

Detailed description

same as above

Conditions

• Cellulitis

Interventions

Type	Name	Description
DRUG	Daptomycin
DRUG	Vancomycin

Timeline

• Start date: 2006-02-20
• Primary completion: 2006-08-09
• Completion: 2006-08-09
• First posted: 2006-02-23
• Last updated: 2017-09-07

Locations

1 site across 1 country: United States